Nitric Oxide-Releasing Topical Therapeutic Agent for Atopic Dermatitis

The document reported on the effectiveness of SB414, a nitric oxide-releasing topical agent, in treating atopic dermatitis (AD). In a murine model, SB414 achieved a dose-dependent reduction in ear swelling, with the highest dose (6.0%) significantly reducing swelling by 5%, compared to an 80% reduction with 0.05% betamethasone cream. Additionally, in a porcine skin wound model infected with S. aureus, SB414 significantly reduced bacterial counts in a dose-dependent manner, with the highest dose showing a greater than 3-log reduction after five treatments. These findings indicate that SB414 could be a promising therapy for AD by modulating immune responses and decreasing S. aureus skin colonization.